PMC:7600245 / 48414-49588 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T213","span":{"begin":205,"end":213},"obj":"Body_part"},{"id":"T214","span":{"begin":798,"end":805},"obj":"Body_part"},{"id":"T215","span":{"begin":896,"end":901},"obj":"Body_part"},{"id":"T216","span":{"begin":936,"end":945},"obj":"Body_part"},{"id":"T217","span":{"begin":1147,"end":1155},"obj":"Body_part"}],"attributes":[{"id":"A213","pred":"fma_id","subj":"T213","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A214","pred":"fma_id","subj":"T214","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A215","pred":"fma_id","subj":"T215","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A216","pred":"fma_id","subj":"T216","obj":"http://purl.org/sig/ont/fma/fma9639"},{"id":"A217","pred":"fma_id","subj":"T217","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":"The drug has been reported to exhibit antiviral activity against influenza A and B viruses with IC50 values in the low micromolar range. In this arena, naproxen antagonized CRM1-mediated nuclear export of proteins of influenza A and B viruses. Naproxen also provided therapeutic protection to mice infected with influenza B virus [150,151]. In hospitalized patients with influenza, it was found that adding clarithromycin and naproxen to oseltamivir shortened the hospitalization time [150,151]. Naproxen also inhibited the replication of Zika virus by reducing the expression of AXL, the entry cofactor of Zika virus [152]. Naproxen’s antiviral activity against SARS-CoV-2 has also been proposed by a recent computational work and has been attributed its ability to bind to the viral nucleocapsid protein. In fact, it was recently reported that naproxen inhibits SARS-CoV-2 infection in Vero E6 cells and in reconstituted human airway epithelia with IC50 values comparable to those effective in influenza [153]. Lastly, similar to indomethacin, the anti-inflammatory effects of naproxen may also translate into beneficial effects in treating the cytokine storm of COVID-19."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T17","span":{"begin":936,"end":945},"obj":"Body_part"}],"attributes":[{"id":"A17","pred":"uberon_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/UBERON_0000483"}],"text":"The drug has been reported to exhibit antiviral activity against influenza A and B viruses with IC50 values in the low micromolar range. In this arena, naproxen antagonized CRM1-mediated nuclear export of proteins of influenza A and B viruses. Naproxen also provided therapeutic protection to mice infected with influenza B virus [150,151]. In hospitalized patients with influenza, it was found that adding clarithromycin and naproxen to oseltamivir shortened the hospitalization time [150,151]. Naproxen also inhibited the replication of Zika virus by reducing the expression of AXL, the entry cofactor of Zika virus [152]. Naproxen’s antiviral activity against SARS-CoV-2 has also been proposed by a recent computational work and has been attributed its ability to bind to the viral nucleocapsid protein. In fact, it was recently reported that naproxen inhibits SARS-CoV-2 infection in Vero E6 cells and in reconstituted human airway epithelia with IC50 values comparable to those effective in influenza [153]. Lastly, similar to indomethacin, the anti-inflammatory effects of naproxen may also translate into beneficial effects in treating the cytokine storm of COVID-19."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T202","span":{"begin":65,"end":74},"obj":"Disease"},{"id":"T203","span":{"begin":217,"end":226},"obj":"Disease"},{"id":"T204","span":{"begin":312,"end":321},"obj":"Disease"},{"id":"T205","span":{"begin":371,"end":380},"obj":"Disease"},{"id":"T206","span":{"begin":539,"end":543},"obj":"Disease"},{"id":"T207","span":{"begin":607,"end":611},"obj":"Disease"},{"id":"T208","span":{"begin":663,"end":671},"obj":"Disease"},{"id":"T209","span":{"begin":864,"end":872},"obj":"Disease"},{"id":"T210","span":{"begin":875,"end":884},"obj":"Disease"},{"id":"T211","span":{"begin":996,"end":1005},"obj":"Disease"},{"id":"T212","span":{"begin":1165,"end":1173},"obj":"Disease"}],"attributes":[{"id":"A202","pred":"mondo_id","subj":"T202","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A203","pred":"mondo_id","subj":"T203","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A204","pred":"mondo_id","subj":"T204","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A205","pred":"mondo_id","subj":"T205","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A206","pred":"mondo_id","subj":"T206","obj":"http://purl.obolibrary.org/obo/MONDO_0018661"},{"id":"A207","pred":"mondo_id","subj":"T207","obj":"http://purl.obolibrary.org/obo/MONDO_0018661"},{"id":"A208","pred":"mondo_id","subj":"T208","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A209","pred":"mondo_id","subj":"T209","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A210","pred":"mondo_id","subj":"T210","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A211","pred":"mondo_id","subj":"T211","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A212","pred":"mondo_id","subj":"T212","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"The drug has been reported to exhibit antiviral activity against influenza A and B viruses with IC50 values in the low micromolar range. In this arena, naproxen antagonized CRM1-mediated nuclear export of proteins of influenza A and B viruses. Naproxen also provided therapeutic protection to mice infected with influenza B virus [150,151]. In hospitalized patients with influenza, it was found that adding clarithromycin and naproxen to oseltamivir shortened the hospitalization time [150,151]. Naproxen also inhibited the replication of Zika virus by reducing the expression of AXL, the entry cofactor of Zika virus [152]. Naproxen’s antiviral activity against SARS-CoV-2 has also been proposed by a recent computational work and has been attributed its ability to bind to the viral nucleocapsid protein. In fact, it was recently reported that naproxen inhibits SARS-CoV-2 infection in Vero E6 cells and in reconstituted human airway epithelia with IC50 values comparable to those effective in influenza [153]. Lastly, similar to indomethacin, the anti-inflammatory effects of naproxen may also translate into beneficial effects in treating the cytokine storm of COVID-19."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T474","span":{"begin":9,"end":12},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T475","span":{"begin":48,"end":56},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T476","span":{"begin":75,"end":76},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T477","span":{"begin":81,"end":82},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T478","span":{"begin":83,"end":90},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T479","span":{"begin":227,"end":228},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T480","span":{"begin":233,"end":234},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T481","span":{"begin":235,"end":242},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T482","span":{"begin":322,"end":323},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T483","span":{"begin":324,"end":329},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T484","span":{"begin":544,"end":549},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T485","span":{"begin":612,"end":617},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T486","span":{"begin":646,"end":654},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T487","span":{"begin":674,"end":677},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T488","span":{"begin":700,"end":701},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T489","span":{"begin":732,"end":735},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T490","span":{"begin":888,"end":901},"obj":"http://purl.obolibrary.org/obo/CLO_0051719"},{"id":"T491","span":{"begin":923,"end":928},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T492","span":{"begin":929,"end":935},"obj":"http://purl.obolibrary.org/obo/UBERON_0001005"}],"text":"The drug has been reported to exhibit antiviral activity against influenza A and B viruses with IC50 values in the low micromolar range. In this arena, naproxen antagonized CRM1-mediated nuclear export of proteins of influenza A and B viruses. Naproxen also provided therapeutic protection to mice infected with influenza B virus [150,151]. In hospitalized patients with influenza, it was found that adding clarithromycin and naproxen to oseltamivir shortened the hospitalization time [150,151]. Naproxen also inhibited the replication of Zika virus by reducing the expression of AXL, the entry cofactor of Zika virus [152]. Naproxen’s antiviral activity against SARS-CoV-2 has also been proposed by a recent computational work and has been attributed its ability to bind to the viral nucleocapsid protein. In fact, it was recently reported that naproxen inhibits SARS-CoV-2 infection in Vero E6 cells and in reconstituted human airway epithelia with IC50 values comparable to those effective in influenza [153]. Lastly, similar to indomethacin, the anti-inflammatory effects of naproxen may also translate into beneficial effects in treating the cytokine storm of COVID-19."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T696","span":{"begin":4,"end":8},"obj":"Chemical"},{"id":"T697","span":{"begin":38,"end":47},"obj":"Chemical"},{"id":"T698","span":{"begin":152,"end":160},"obj":"Chemical"},{"id":"T700","span":{"begin":205,"end":213},"obj":"Chemical"},{"id":"T701","span":{"begin":244,"end":252},"obj":"Chemical"},{"id":"T702","span":{"begin":407,"end":421},"obj":"Chemical"},{"id":"T703","span":{"begin":426,"end":434},"obj":"Chemical"},{"id":"T705","span":{"begin":438,"end":449},"obj":"Chemical"},{"id":"T706","span":{"begin":496,"end":504},"obj":"Chemical"},{"id":"T707","span":{"begin":595,"end":603},"obj":"Chemical"},{"id":"T708","span":{"begin":636,"end":645},"obj":"Chemical"},{"id":"T709","span":{"begin":798,"end":805},"obj":"Chemical"},{"id":"T710","span":{"begin":846,"end":854},"obj":"Chemical"},{"id":"T712","span":{"begin":1079,"end":1087},"obj":"Chemical"}],"attributes":[{"id":"A696","pred":"chebi_id","subj":"T696","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A697","pred":"chebi_id","subj":"T697","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A698","pred":"chebi_id","subj":"T698","obj":"http://purl.obolibrary.org/obo/CHEBI_59527"},{"id":"A699","pred":"chebi_id","subj":"T698","obj":"http://purl.obolibrary.org/obo/CHEBI_7476"},{"id":"A700","pred":"chebi_id","subj":"T700","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A701","pred":"chebi_id","subj":"T701","obj":"http://purl.obolibrary.org/obo/CHEBI_7476"},{"id":"A702","pred":"chebi_id","subj":"T702","obj":"http://purl.obolibrary.org/obo/CHEBI_3732"},{"id":"A703","pred":"chebi_id","subj":"T703","obj":"http://purl.obolibrary.org/obo/CHEBI_59527"},{"id":"A704","pred":"chebi_id","subj":"T703","obj":"http://purl.obolibrary.org/obo/CHEBI_7476"},{"id":"A705","pred":"chebi_id","subj":"T705","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A706","pred":"chebi_id","subj":"T706","obj":"http://purl.obolibrary.org/obo/CHEBI_7476"},{"id":"A707","pred":"chebi_id","subj":"T707","obj":"http://purl.obolibrary.org/obo/CHEBI_23357"},{"id":"A708","pred":"chebi_id","subj":"T708","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A709","pred":"chebi_id","subj":"T709","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A710","pred":"chebi_id","subj":"T710","obj":"http://purl.obolibrary.org/obo/CHEBI_59527"},{"id":"A711","pred":"chebi_id","subj":"T710","obj":"http://purl.obolibrary.org/obo/CHEBI_7476"},{"id":"A712","pred":"chebi_id","subj":"T712","obj":"http://purl.obolibrary.org/obo/CHEBI_59527"},{"id":"A713","pred":"chebi_id","subj":"T712","obj":"http://purl.obolibrary.org/obo/CHEBI_7476"}],"text":"The drug has been reported to exhibit antiviral activity against influenza A and B viruses with IC50 values in the low micromolar range. In this arena, naproxen antagonized CRM1-mediated nuclear export of proteins of influenza A and B viruses. Naproxen also provided therapeutic protection to mice infected with influenza B virus [150,151]. In hospitalized patients with influenza, it was found that adding clarithromycin and naproxen to oseltamivir shortened the hospitalization time [150,151]. Naproxen also inhibited the replication of Zika virus by reducing the expression of AXL, the entry cofactor of Zika virus [152]. Naproxen’s antiviral activity against SARS-CoV-2 has also been proposed by a recent computational work and has been attributed its ability to bind to the viral nucleocapsid protein. In fact, it was recently reported that naproxen inhibits SARS-CoV-2 infection in Vero E6 cells and in reconstituted human airway epithelia with IC50 values comparable to those effective in influenza [153]. Lastly, similar to indomethacin, the anti-inflammatory effects of naproxen may also translate into beneficial effects in treating the cytokine storm of COVID-19."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T83","span":{"begin":187,"end":201},"obj":"http://purl.obolibrary.org/obo/GO_0051168"}],"text":"The drug has been reported to exhibit antiviral activity against influenza A and B viruses with IC50 values in the low micromolar range. In this arena, naproxen antagonized CRM1-mediated nuclear export of proteins of influenza A and B viruses. Naproxen also provided therapeutic protection to mice infected with influenza B virus [150,151]. In hospitalized patients with influenza, it was found that adding clarithromycin and naproxen to oseltamivir shortened the hospitalization time [150,151]. Naproxen also inhibited the replication of Zika virus by reducing the expression of AXL, the entry cofactor of Zika virus [152]. Naproxen’s antiviral activity against SARS-CoV-2 has also been proposed by a recent computational work and has been attributed its ability to bind to the viral nucleocapsid protein. In fact, it was recently reported that naproxen inhibits SARS-CoV-2 infection in Vero E6 cells and in reconstituted human airway epithelia with IC50 values comparable to those effective in influenza [153]. Lastly, similar to indomethacin, the anti-inflammatory effects of naproxen may also translate into beneficial effects in treating the cytokine storm of COVID-19."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T47","span":{"begin":1147,"end":1161},"obj":"Phenotype"}],"attributes":[{"id":"A47","pred":"hp_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/HP_0033041"}],"text":"The drug has been reported to exhibit antiviral activity against influenza A and B viruses with IC50 values in the low micromolar range. In this arena, naproxen antagonized CRM1-mediated nuclear export of proteins of influenza A and B viruses. Naproxen also provided therapeutic protection to mice infected with influenza B virus [150,151]. In hospitalized patients with influenza, it was found that adding clarithromycin and naproxen to oseltamivir shortened the hospitalization time [150,151]. Naproxen also inhibited the replication of Zika virus by reducing the expression of AXL, the entry cofactor of Zika virus [152]. Naproxen’s antiviral activity against SARS-CoV-2 has also been proposed by a recent computational work and has been attributed its ability to bind to the viral nucleocapsid protein. In fact, it was recently reported that naproxen inhibits SARS-CoV-2 infection in Vero E6 cells and in reconstituted human airway epithelia with IC50 values comparable to those effective in influenza [153]. Lastly, similar to indomethacin, the anti-inflammatory effects of naproxen may also translate into beneficial effects in treating the cytokine storm of COVID-19."}

{"project":"LitCovid-sentences","denotations":[{"id":"T361","span":{"begin":0,"end":136},"obj":"Sentence"},{"id":"T362","span":{"begin":137,"end":243},"obj":"Sentence"},{"id":"T363","span":{"begin":244,"end":340},"obj":"Sentence"},{"id":"T364","span":{"begin":341,"end":495},"obj":"Sentence"},{"id":"T365","span":{"begin":496,"end":624},"obj":"Sentence"},{"id":"T366","span":{"begin":625,"end":806},"obj":"Sentence"},{"id":"T367","span":{"begin":807,"end":1012},"obj":"Sentence"},{"id":"T368","span":{"begin":1013,"end":1174},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The drug has been reported to exhibit antiviral activity against influenza A and B viruses with IC50 values in the low micromolar range. In this arena, naproxen antagonized CRM1-mediated nuclear export of proteins of influenza A and B viruses. Naproxen also provided therapeutic protection to mice infected with influenza B virus [150,151]. In hospitalized patients with influenza, it was found that adding clarithromycin and naproxen to oseltamivir shortened the hospitalization time [150,151]. Naproxen also inhibited the replication of Zika virus by reducing the expression of AXL, the entry cofactor of Zika virus [152]. Naproxen’s antiviral activity against SARS-CoV-2 has also been proposed by a recent computational work and has been attributed its ability to bind to the viral nucleocapsid protein. In fact, it was recently reported that naproxen inhibits SARS-CoV-2 infection in Vero E6 cells and in reconstituted human airway epithelia with IC50 values comparable to those effective in influenza [153]. Lastly, similar to indomethacin, the anti-inflammatory effects of naproxen may also translate into beneficial effects in treating the cytokine storm of COVID-19."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1527","span":{"begin":173,"end":177},"obj":"Gene"},{"id":"1528","span":{"begin":580,"end":583},"obj":"Gene"},{"id":"1529","span":{"begin":217,"end":234},"obj":"Gene"},{"id":"1530","span":{"begin":65,"end":82},"obj":"Gene"},{"id":"1531","span":{"begin":785,"end":797},"obj":"Gene"},{"id":"1532","span":{"begin":293,"end":297},"obj":"Species"},{"id":"1533","span":{"begin":312,"end":329},"obj":"Species"},{"id":"1534","span":{"begin":357,"end":365},"obj":"Species"},{"id":"1535","span":{"begin":539,"end":549},"obj":"Species"},{"id":"1536","span":{"begin":607,"end":617},"obj":"Species"},{"id":"1537","span":{"begin":663,"end":673},"obj":"Species"},{"id":"1538","span":{"begin":923,"end":928},"obj":"Species"},{"id":"1539","span":{"begin":371,"end":380},"obj":"Species"},{"id":"1540","span":{"begin":996,"end":1005},"obj":"Species"},{"id":"1541","span":{"begin":152,"end":160},"obj":"Chemical"},{"id":"1542","span":{"begin":244,"end":252},"obj":"Chemical"},{"id":"1543","span":{"begin":407,"end":421},"obj":"Chemical"},{"id":"1544","span":{"begin":426,"end":434},"obj":"Chemical"},{"id":"1545","span":{"begin":438,"end":449},"obj":"Chemical"},{"id":"1546","span":{"begin":496,"end":504},"obj":"Chemical"},{"id":"1547","span":{"begin":846,"end":854},"obj":"Chemical"},{"id":"1548","span":{"begin":1032,"end":1044},"obj":"Chemical"},{"id":"1549","span":{"begin":1079,"end":1087},"obj":"Chemical"},{"id":"1550","span":{"begin":298,"end":306},"obj":"Disease"},{"id":"1551","span":{"begin":864,"end":884},"obj":"Disease"},{"id":"1552","span":{"begin":1165,"end":1173},"obj":"Disease"},{"id":"1553","span":{"begin":888,"end":895},"obj":"CellLine"}],"attributes":[{"id":"A1527","pred":"tao:has_database_id","subj":"1527","obj":"Gene:7514"},{"id":"A1528","pred":"tao:has_database_id","subj":"1528","obj":"Gene:558"},{"id":"A1531","pred":"tao:has_database_id","subj":"1531","obj":"Gene:43740575"},{"id":"A1532","pred":"tao:has_database_id","subj":"1532","obj":"Tax:10090"},{"id":"A1533","pred":"tao:has_database_id","subj":"1533","obj":"Tax:11520"},{"id":"A1534","pred":"tao:has_database_id","subj":"1534","obj":"Tax:9606"},{"id":"A1535","pred":"tao:has_database_id","subj":"1535","obj":"Tax:64320"},{"id":"A1536","pred":"tao:has_database_id","subj":"1536","obj":"Tax:64320"},{"id":"A1537","pred":"tao:has_database_id","subj":"1537","obj":"Tax:2697049"},{"id":"A1538","pred":"tao:has_database_id","subj":"1538","obj":"Tax:9606"},{"id":"A1539","pred":"tao:has_database_id","subj":"1539","obj":"Tax:11520"},{"id":"A1540","pred":"tao:has_database_id","subj":"1540","obj":"Tax:11520"},{"id":"A1541","pred":"tao:has_database_id","subj":"1541","obj":"MESH:D009288"},{"id":"A1542","pred":"tao:has_database_id","subj":"1542","obj":"MESH:D009288"},{"id":"A1543","pred":"tao:has_database_id","subj":"1543","obj":"MESH:D017291"},{"id":"A1544","pred":"tao:has_database_id","subj":"1544","obj":"MESH:D009288"},{"id":"A1545","pred":"tao:has_database_id","subj":"1545","obj":"MESH:D053139"},{"id":"A1546","pred":"tao:has_database_id","subj":"1546","obj":"MESH:D009288"},{"id":"A1547","pred":"tao:has_database_id","subj":"1547","obj":"MESH:D009288"},{"id":"A1548","pred":"tao:has_database_id","subj":"1548","obj":"MESH:D007213"},{"id":"A1549","pred":"tao:has_database_id","subj":"1549","obj":"MESH:D009288"},{"id":"A1550","pred":"tao:has_database_id","subj":"1550","obj":"MESH:D007239"},{"id":"A1551","pred":"tao:has_database_id","subj":"1551","obj":"MESH:C000657245"},{"id":"A1552","pred":"tao:has_database_id","subj":"1552","obj":"MESH:C000657245"},{"id":"A1553","pred":"tao:has_database_id","subj":"1553","obj":"CVCL:0574"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The drug has been reported to exhibit antiviral activity against influenza A and B viruses with IC50 values in the low micromolar range. In this arena, naproxen antagonized CRM1-mediated nuclear export of proteins of influenza A and B viruses. Naproxen also provided therapeutic protection to mice infected with influenza B virus [150,151]. In hospitalized patients with influenza, it was found that adding clarithromycin and naproxen to oseltamivir shortened the hospitalization time [150,151]. Naproxen also inhibited the replication of Zika virus by reducing the expression of AXL, the entry cofactor of Zika virus [152]. Naproxen’s antiviral activity against SARS-CoV-2 has also been proposed by a recent computational work and has been attributed its ability to bind to the viral nucleocapsid protein. In fact, it was recently reported that naproxen inhibits SARS-CoV-2 infection in Vero E6 cells and in reconstituted human airway epithelia with IC50 values comparable to those effective in influenza [153]. Lastly, similar to indomethacin, the anti-inflammatory effects of naproxen may also translate into beneficial effects in treating the cytokine storm of COVID-19."}